🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

READ: 130-page cheat sheet outlining key #MachineLearning concepts: bit.ly/130pgMLsheet

Sacituzumab govitecan (SG) in patients with advanced endometrial cancer (from TROPiCS-03) TROP2 expression didn’t correlate with efficacy, and PFS was similar between subgroups, suggesting that response to SG is observed regardless of the level of TROP2 ascopubs.org/doi/10.1200/JC…

Fascinating study on aging — and some very sad news for my fellow 44-year-olds (in case you weren't already feeling a bit old!)

Updated (non-exhaustive) breast cancer treatment algorithms, now including adjuvant ribociclib and other recent updates. I am happy to be running out of space as treatment options continue to expand! OncoAlert #bcsm

Bispecific antibodies (bsAbs) allow therapeutic applications that cannot be achieved using conventional antibodies. There are 14 bsAbs approved: 11 for cancer & 3 for non-oncology indications. This review summarizes this very active field, including bsAb signaling pathway

Pan-cancer proteogenomics expands the landscape of therapeutic targets - PubMed pubmed.ncbi.nlm.nih.gov/38917788/

New paper from our group in nature by Yiyun Lin @junkewang Kaile Wang and team reporting the unexpected discovery of aneuploid epithelial cells (3%) in normal breast tissues from healthy women raising the question of when is cancer really cancer? nature.com/articles/s4158…

Two weeks to #SABCS24. Here’s 10 presentations you can’t miss at the conference. #bcsm

In 15+ years at Amazon, I influenced 30+ promotions to the Director level. I know why some people get promoted while other "top performers" get overlooked. Here's what you need to know:

A record 77 new ADCs entered clinical development in 2024 (including those accepted but not yet started). Payload class was clearly dominated by topo1i with 55 ADCs. Greater diversity was observed in antibody targets, featuring novel TAAs and several bispecific ADCs.

AI is hyped as the future of drug development. But has it really changed the game? Let’s break down where AI stands and what’s missing. 🧵

Another synthetic lethal target in the recurrent 9p21 deletion observed in many solid cancers, including #glioblastoma and #PancreaticCancer (MTAP being the other one thats being targeted by PRMT5i) Superkiller complex problems expose a cancer-cell vulnerability

It’s been a tough few weeks. My 10yo daughter was diagnosed with a very rare, aggressive cancer called interdigitating dendritic cell sarcoma (IDCS). I’m reaching out to identify clinicians/patients who have encountered pediatric IDCS, indeterminate dendritic cell histiocytosis

Of >105,000 participants with 30-year follow-up, only 9.3% achieved healthy aging (age 70, w/o any chronic diseases). Their diet was significantly associated with this outcome🧵 Nature Medicine

Always great to hear the original RAScal Channing Der Der Lab at UNC talk about KRAS & KRAS inhibitors. Thanks to Channing and his team for putting together such great overview slides. As of March 2025, there are 45 inhibitors (!) & 160 clinical trials. Absolutely amazing. David S. Hong MD

Evolution of HER2 testing over 40 yrs. IHC lacks the dynamic range to predict outcomes with T-DXd, yet novel quantitative assays are emerging. We presented data with HS-HER2 to predict T-DXd activity at #ESMO24. More data coming at #ASCO25. Stay tuned. nature.com/articles/s4157…

A map of microbiome-metabolome dynamics in people with diabetes type 2 identifies over 500 blood metabolites associated with impaired glucose control, with approximately one third linked to an altered gut microbiome. nature.com/articles/s4159…

Agentic AI — what lies beneath! #Infographic source: linkedin.com/posts/stevenou…

First clinical data (small patient #) of a PD-L1 x VEGF-A bispecific + TROP2 ADC combo! #AACR25 #ADC

🧬 MSI-H = hallmark of mismatch repair (MMR) deficiency. 🧵 Prevalence: ~30% endometrial, ~10% CRC, ~8% gastric. But not all MSI-H/dMMR tumors are alike: 1️⃣ MSH2/MSH6 loss → ↑ TMB, better ICI response 2️⃣ PTEN/AKT1 mutations → ICI resistance Checkpoint blockade is now 1L in CRC